Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: serubanja j. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Among authors: serubanja j. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
Genome-wide analysis of Schistosoma mansoni reveals limited population structure and possible praziquantel drug selection pressure within Ugandan hot-spot communities.
Vianney TJ, Berger DJ, Doyle SR, Sankaranarayanan G, Serubanja J, Nakawungu PK, Besigye F, Sanya RE, Holroyd N, Allan F, Webb EL, Elliott AM, Berriman M, Cotton JA. Vianney TJ, et al. Among authors: serubanja j. PLoS Negl Trop Dis. 2022 Aug 18;16(8):e0010188. doi: 10.1371/journal.pntd.0010188. eCollection 2022 Aug. PLoS Negl Trop Dis. 2022. PMID: 35981002 Free PMC article.
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb E, Elliott AM; POPVAC trial team. Zirimenya L, et al. Among authors: serubanja j. BMJ Open. 2021 Feb 16;11(2):e040430. doi: 10.1136/bmjopen-2020-040430. BMJ Open. 2021. PMID: 33593770 Free PMC article.
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Oduru G, Amongin R, Kabuubi PN, Mutebe A, Onen C, Amongi S, Nakazibwe E, Akello F, Kiwanuka S, Kiwudhu F, Sewankambo M, Nsubuga D, Kizindo R, Staedke SG, Cose S, Webb E, Elliott AM; POPVAC trial team. Natukunda A, et al. BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427. BMJ Open. 2021. PMID: 33593769 Free PMC article.
Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Nkurunungi G, Zirimenya L, Nassuuna J, Natukunda A, Kabuubi PN, Niwagaba E, Oduru G, Kabami G, Amongin R, Mutebe A, Namutebi M, Zziwa C, Amongi S, Ninsiima C, Onen C, Akello F, Sewankambo M, Kiwanuka S, Kizindo R, Kaweesa J, Cose S, Webb E, Elliott AM; POPVAC trial team; POPVAC trial team principal investigator. Nkurunungi G, et al. BMJ Open. 2021 Feb 16;11(2):e040426. doi: 10.1136/bmjopen-2020-040426. BMJ Open. 2021. PMID: 33593768 Free PMC article.
Maternal Latent Mycobacterium tuberculosis Does Not Affect the Infant Immune Response Following BCG at Birth: An Observational Longitudinal Study in Uganda.
Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, Serubanja J, Aibo D, Akurut H, Tumusiime J, Hasso-Agopsowicz M, Kaleebu P, Levin J, Dockrell HM, Smith S, Webb EL, Elliott AM, Cose S. Lubyayi L, et al. Among authors: serubanja j. Front Immunol. 2020 May 14;11:929. doi: 10.3389/fimmu.2020.00929. eCollection 2020. Front Immunol. 2020. PMID: 32477371 Free PMC article.
Does Intensive Treatment Select for Praziquantel Resistance in High-Transmission Settings? Parasitological Trends and Treatment Efficacy Within a Cluster-Randomized Trial.
Tushabe JV, Lubyayi L, Sserubanja J, Kabuubi P, Abayo E, Kiwanuka S, Nassuuna J, Kaweesa J, Corstjens P, van Dam G, Sanya RE, Ssenyonga W, Tukahebwa EM, Kabatereine NB, Elliott AM, Webb EL; LaVIISWA trial team. Tushabe JV, et al. Open Forum Infect Dis. 2020 Mar 12;7(4):ofaa091. doi: 10.1093/ofid/ofaa091. eCollection 2020 Apr. Open Forum Infect Dis. 2020. PMID: 32296727 Free PMC article.